胃肠胰神经内分泌肿瘤临床治疗与基础研究现状及进展

Advances in clinical and basic research of gastroenteropancreatic neuroendocrine neoplasms

胃肠胰神经内分泌肿瘤(gastroenter opancreatic neuroendocrine neoplasms,GEPNENs)是一组相对少见的肿瘤,主要起源于胃肠道及胰腺的肽能神经元和神经内分泌细胞,其特征是可以产生多肽激素和神经内分泌标志物(如突触囊泡蛋白、嗜铬粒素A).早期GEP-NENs的治疗最为有效的途径是手术.对于进展期GEP-NENs来讲,生物靶向治疗已成为当前热门研究方向,目前生物靶向治疗药物的研究均与其基因突变及相关信号通路有关,部分研究成果已应用于临床并取得重大进展,因此,本文对GEP-NENs生物靶向治疗药物的临床研究与动物学、细胞学模型研究作一综述.

Gastroentero-pancreatic neuroendocrine neoplasms（GEP-NENs） are a group of relatively rare tumors,which mainly originate from the peptidergic neuron and neuroendocrine cells of the gastroentero-pancreatic system.They are characterized by secretion of peptide hormones and neuroendocrine markers（such as synaptic vesicle proteins and chromaffin granule A）.Surgery is the most effective therapy for GEP-NENs at early stages.ForGEP-NENs at progressive stages,biological target therapies have aroused great interest.Current studies about the molecular basis of biological target therapies have focused on the GEP-NEN gene mutations and related signaling pathways.These studies have led to the clinical application with significant progress in GEP-NEN treatment.In this paper,we review the recent advances in the clinical and basic research of GEP-NENs.